История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $30.5B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B | $24.7B | $22.4B | $22.1B | $26.1B | $30.4B | $32.6B | $24.9B | $11.2B | $9.7B | $8.4B | $7.9B | $7.0B | $5.3B | $4.2B | $3.0B |
| Валовая прибыль | $24.2B | $23.2B | $22.5B | $27.1B | $21.6B | $20.7B | $20.1B | $17.8B | $17.3B | $21.7B | $26.1B | $28.6B | $21.1B | $8.3B | $7.2B | $6.3B | $6.1B | $5.4B | $4.2B | $3.5B | $2.6B |
| Валовая маржа % | 79.6% | 78.8% | 78.3% | 100.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% | 87.7% | 84.8% | 74.5% | 74.5% | 74.7% | 76.5% | 77.2% | 78.9% | 81.8% | 85.7% |
| Операционная прибыль (EBIT) | ($1.4B) | $11.7B | $1.7B | $7.6B | $7.3B | $9.9B | $4.1B | $4.3B | $8.2B | $14.1B | $17.6B | $22.2B | $15.3B | $4.5B | $4.0B | $3.8B | $4.0B | $3.5B | $2.7B | $2.2B | ($759M) |
| Операционная маржа % | -4.5% | 39.7% | 5.8% | 28.1% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% | 68.0% | 61.3% | 40.4% | 41.3% | 45.2% | 49.8% | 50.3% | 50.2% | 51.2% | -25.1% |
| Чистая прибыль | ($3.2B) | $8.5B | $480M | $5.7B | $4.6B | $6.2B | $123M | $5.4B | $5.5B | $4.6B | $13.5B | $18.1B | $12.1B | $3.1B | $2.6B | $2.8B | $2.9B | $2.6B | $2.0B | $1.6B | ($1.2B) |
| Чистая маржа % | -10.6% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.6% | 17.7% | 44.4% | 55.5% | 48.6% | 27.5% | 26.7% | 33.4% | 36.5% | 37.6% | 37.1% | 38.2% | -39.3% |
| EBITDA | $1.1B | $13.6B | $4.4B | $7.6B | $8.9B | $11.3B | $4.1B | $7.6B | $10.3B | $15.9B | $19.2B | $23.4B | $16.3B | $4.9B | $4.3B | $4.2B | $4.3B | $3.8B | $2.9B | $2.2B | $1.7B |
| Прибыль на акцию (EPS) | $-2.66 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $1.41 | $1.03 | $0.84 | $-0.65 |
| Акции в обращении (M) | 1,243M | 1,255M | 1,255M | 1,258M | 1,262M | 1,262M | 1,263M | 1,277M | 1,308M | 1,319M | 1,358M | 1,521M | 1,647M | 1,695M | 1,583M | 1,580M | 1,747M | 1,868M | 1,918M | 1,929M | 1,836M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике GILD. /companies/us/GILD
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms